Tarsus Pharmaceuticals Inc
General ticker "TARS" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $2.0B
Tarsus Pharmaceuticals Inc follows the US Stock Market performance with the rate: 44.6%.
Estimated limits based on current volatility of 2.7%: low 52.15$, high 55.04$
Factors to consider:
- Current price 124.3% above estimated high
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [11.90$, 24.09$]
- 2024-12-30 to 2025-12-30 estimated range: [10.58$, 21.65$]
Financial Metrics affecting the TARS estimates:
- Negative: Non-GAAP EPS, $ of -4.64 <= 0.10
- Negative: Operating profit margin, % of -89.14 <= 1.03
- Negative: Operating cash flow per share per price, % of -18.24 <= 2.35
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -12.63 <= 3.85
- Positive: Interest expense per share, $ of 0.11 <= 0.14
- Positive: Industry inventory ratio change (median), % of -2.41 <= -0.39
Short-term TARS quotes
Long-term TARS plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $57.03MM | $25.82MM | $17.45MM |
| Operating Expenses | $69.18MM | $88.53MM | $160.60MM |
| Operating Income | $-12.16MM | $-62.71MM | $-143.16MM |
| Non-Operating Income | $-1.61MM | $0.62MM | $7.26MM |
| Interest Expense | $0.00MM | $2.20MM | $3.35MM |
| R&D Expense | $41.71MM | $42.62MM | $50.31MM |
| Income(Loss) | $-13.77MM | $-62.09MM | $-135.89MM |
| Taxes | $0.06MM | $-0.00MM | $0.00MM |
| Profit(Loss) | $-13.83MM | $-62.09MM | $-135.89MM |
| Stockholders Equity | $166.73MM | $192.90MM | $196.99MM |
| Inventory | $0.00MM | $4.76MM | $3.11MM |
| Assets | $178.91MM | $227.86MM | $265.49MM |
| Operating Cash Flow | $3.75MM | $-49.03MM | $-117.49MM |
| Capital expenditure | $0.59MM | $0.51MM | $1.50MM |
| Investing Cash Flow | $-0.59MM | $-144.63MM | $140.60MM |
| Financing Cash Flow | $0.02MM | $93.99MM | $130.18MM |
| Earnings Per Share* | $-0.67 | $-2.52 | $-4.62 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.